Advertisement
BHC vs SUPN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BHC is a Hold and SUPN is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BHC’s FA Score shows that 0 FA rating(s) are green whileSUPN’s FA Score has 0 green FA rating(s).
- BHC’s FA Score: 0 green, 5 red.
- SUPN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BHC’s TA Score shows that 5 TA indicator(s) are bullish while SUPN’s TA Score has 3 bullish TA indicator(s).
- BHC’s TA Score: 5 bullish, 5 bearish.
- SUPN’s TA Score: 3 bullish, 4 bearish.
Price Growth
BHC (@Pharmaceuticals: Other) experienced а +15.95% price change this week, while SUPN (@Pharmaceuticals: Other) price change was -0.57% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.24%. For the same industry, the average monthly price growth was +14.55%, and the average quarterly price growth was +157.18%.
Reported Earning Dates
BHC is expected to report earnings on Jul 30, 2025.
SUPN is expected to report earnings on Jul 31, 2025.
Industries' Descriptions
@Pharmaceuticals: Other (+0.24% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| BHC | SUPN | BHC / SUPN | |
| Capitalization | 3.86B | 1.84B | 210% |
| EBITDA | 2.2B | 90M | 2,447% |
| Gain YTD | -23.325 | -10.730 | 217% |
| P/E Ratio | 13.39 | 1677.00 | 1% |
| Revenue | 8.76B | 608M | 1,440% |
| Total Cash | 947M | 255M | 371% |
| Total Debt | 22.4B | 41.5M | 53,976% |
BHC | SUPN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 46 | 79 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 35 Fair valued | 75 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 63 | |
SMR RATING 1..100 | 100 | 80 | |
PRICE GROWTH RATING 1..100 | 47 | 53 | |
P/E GROWTH RATING 1..100 | 98 | 100 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BHC's Valuation (35) in the Pharmaceuticals Other industry is somewhat better than the same rating for SUPN (75). This means that BHC’s stock grew somewhat faster than SUPN’s over the last 12 months.
SUPN's Profit vs Risk Rating (63) in the Pharmaceuticals Other industry is somewhat better than the same rating for BHC (100). This means that SUPN’s stock grew somewhat faster than BHC’s over the last 12 months.
SUPN's SMR Rating (80) in the Pharmaceuticals Other industry is in the same range as BHC (100). This means that SUPN’s stock grew similarly to BHC’s over the last 12 months.
BHC's Price Growth Rating (47) in the Pharmaceuticals Other industry is in the same range as SUPN (53). This means that BHC’s stock grew similarly to SUPN’s over the last 12 months.
BHC's P/E Growth Rating (98) in the Pharmaceuticals Other industry is in the same range as SUPN (100). This means that BHC’s stock grew similarly to SUPN’s over the last 12 months.
| BHC | SUPN | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 87% | N/A |
| Stochastic ODDS (%) | 3 days ago 80% | 3 days ago 64% |
| Momentum ODDS (%) | 3 days ago 73% | 3 days ago 80% |
| MACD ODDS (%) | 3 days ago 74% | 3 days ago 68% |
| TrendWeek ODDS (%) | 3 days ago 72% | 3 days ago 65% |
| TrendMonth ODDS (%) | 3 days ago 69% | 3 days ago 69% |
| Advances ODDS (%) | 8 days ago 73% | 12 days ago 73% |
| Declines ODDS (%) | 19 days ago 78% | 8 days ago 67% |
| BollingerBands ODDS (%) | 3 days ago 86% | 3 days ago 71% |
| Aroon ODDS (%) | 3 days ago 74% | N/A |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PVAL | 39.08 | 0.08 | +0.21% |
| Putnam Focused Large Cap Value ETF | |||
| YSEP | 23.90 | N/A | +0.02% |
| FT Vest Intl Eq Mod Bfr ETF Sep | |||
| IBMS | 25.54 | -0.02 | -0.08% |
| iShares iBonds Dec 2030 Term Mun Bd ETF | |||
| AVES | 52.73 | -0.06 | -0.11% |
| Avantis Emerging Markets Value ETF | |||
| CAF | 13.35 | -0.15 | -1.11% |
| Morgan Stanley China A Share Fund | |||
SUPN and
Correlation & Price change
A.I.dvisor indicates that over the last year, SUPN has been loosely correlated with DVAX. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if SUPN jumps, then DVAX could also see price increases.
| Ticker / NAME | Correlation To SUPN | 1D Price Change % | ||
|---|---|---|---|---|
| SUPN | 100% | -2.06% | ||
| DVAX - SUPN | 34% Loosely correlated | -3.01% | ||
| COLL - SUPN | 29% Poorly correlated | +0.68% | ||
| SNDL - SUPN | 27% Poorly correlated | -1.57% | ||
| ACET - SUPN | 27% Poorly correlated | +0.15% | ||
| AQST - SUPN | 27% Poorly correlated | -4.12% | ||
More | ||||